Time is of the essence when it comes to drug discovery. MindWalk (NASDAQ: HYFT) combines bio-native AI with in-house wet lab capabilities to accelerate therapy development, making the process safer, faster, and more reliable. President and CEO Dr. Jennifer Bath shares the strategy behind the company’s rebranding, the competitive edge of their LensAI™ platform, and the impact of AI-driven immunogenicity on patient care. From their proven track record to their precise AI technology, discover how MindWalk stands out in the healthcare industry. To learn more about their technology, explore their website: https://www.mindwalkai.com/ Discover MindWalk as an investor: https://ir.ipatherapeutics.com/overview/default.aspx Watch the full YouTube interview here: https://youtu.be/07jQObacjvE And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1
